Health Advances has been successfully advising companies on development and commercialization of high-value diagnostics for the past decade. Our experienced multi-disciplinary team includes PhD researchers, clinical pathologists, and diagnostics industry leaders working to provide innovative strategies for high-value diagnostics.
Successful commercialization of high-value diagnostics depends not only on proof of validity and clinical utility, but also on ensuring widespread access to reimbursement through economic justification.
Client was looking to expand their menu by pursuing tests for synergistic indications.
Assessed the unmet needs in the diagnostic landscape for 10 different diseases through conversations with specialists. Prioritized test opportunities across 14 criteria.
Recommended several potential strategies for the company based on prioritization results, which resulted in test development.
Client with novel screening test had not received broad physician endorsement of their test.
Surveyed patients to show preferences for various screening tests and potential impact of endorsement on screening rates.
Uncovered varying preferences for tests based on underlying patient dynamics. Showed value in endorsing multiple test options. Endorsement of test subsequently attained
Client was looking to secure additional funding for a novel cancer diagnostic test.
Assessed the unmet needs, current diagnostic approaches, and competitive landscape. Estimated adoption based on quantitative survey.
Developed comprehensive sales deck for the client, providing insight into the unmet need and justifiable estimates of future revenues.
Company with complex cancer prognostic test was struggling to gain broad reimbursement and fair pricing for their test.
Mapped existing standard-of-care, as well as change in patient management with novel test. Assessed costs to payer with and without test.
Published findings in leading peer-reviewed journal. Opened door for conversations with commercial and government payers.